<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02762942</url>
  </required_header>
  <id_info>
    <org_study_id>2015-002061-29</org_study_id>
    <secondary_id>2015-002061-29</secondary_id>
    <nct_id>NCT02762942</nct_id>
  </id_info>
  <brief_title>Comparison of Vaginal Misoprostol Plus Supracervical Balloon Versus Vaginal Misoprostol Alone for Induction of Labor</brief_title>
  <official_title>Prospective Randomized Clinical Trial Comparing the Effect of Vaginal Misoprostol Synchronously With Supracervical Balloon Versus Vaginal Misoprostol Alone for Induction of Labor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Consorci Sanitari de Terrassa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Consorci Sanitari de Terrassa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Demonstrate that with concomitant and synchronous use of supracervical balloon and vaginal
      misoprostol for induction of labour, vaginal delivery is achieved in less time compared with
      vaginal misoprostol alone.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Induction to delivery time</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bishop score at 12 hours from the onset of induction</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bishop score at 24 hours from the onset of induction</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of doses of misoprostol required</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of pregnant women requiring oxytocin</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum dosage of oxytocin given (mU / min)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of pregnant women requiring epidural analgesia</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of pregnant women with tachysystole and / or hypertonus with absence of fetal heart rate decelerations</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of pregnant women with tachysystole and / or hypertonus with fetal heart rate decelerations</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of pregnant women with intrapartum fever</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of pregnant women with maternal side effects</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of pregnant women with vaginal delivery within 12 hours from the onset of induction</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of pregnant women with vaginal delivery within 24 hours from the onset of induction</measure>
    <time_frame>through study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total rate of cesarean section</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of cesarean sections for failed induction</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of cesarean sections for nonreassuring fetal status</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal intensive care unit admission</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apgar score at 5 minutes</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Umbilical artery ph</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Induction of Labor</condition>
  <condition>Cervical Ripening</condition>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Vaginal misoprostol alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women in this group will receive 25mcg of vaginal misoprostol every 4 hours up to a maximum of 5 doses. Misoprostol will be stopped in case of a favorable cervix or if the patient is in active labor. In case of no progression after 5 doses of misoprostol, intravenous oxytocin will be perfused 4 hours after the last dose of misoprostol according to local protocols</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaginal misoprostol + Foley catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women in this group will receive 25mcg of vaginal misoprostol every 4 hours up to a maximum of 5 doses. At the same time a 16French Foley catheter will be inserted through the internal os with visualization of the cervix by sterile speculum examination. The catheter balloon will be inflated with 30 ml of sterile normal saline solution and then the catheter will be taped with gentle traction to the inner thigh of the patient until spontaneous expulsion. If this does not occur, the catheter will be deflated and removed after 12 hours. Misoprostol will be stopped in case of a favorable cervix or if the patient is in active labor. In case of no progression after 5 doses of misoprostol, intravenous oxytocin will be perfused 4 hours after the last dose of misoprostol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>Administration of 25 mcg of vaginal misoprostol every 4 hours up to 5 doses</description>
    <arm_group_label>Vaginal misoprostol alone</arm_group_label>
    <arm_group_label>Vaginal misoprostol + Foley catheter</arm_group_label>
    <other_name>Misofar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Foley catheter</intervention_name>
    <description>Insertion of a Foley catheter (16French) through the internal os for a maximum of 12 hours</description>
    <arm_group_label>Vaginal misoprostol + Foley catheter</arm_group_label>
    <other_name>Supracervical balloon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Singleton pregnancy

          -  Cephalic presentation

          -  Reassuring fetal heart rate pattern

          -  Intact membranes

          -  Bishop score less than 6

        Exclusion criteria

          -  Severe preeclampsia

          -  Prematurity ( &lt; 37 weeks gestation dated by first trimester ultrasound)

          -  Previous cesarean section or previous uterine surgery

          -  Intrauterine growth restriction

          -  Premature rupture of membranes

          -  Maternal colonization with Streptococcus Agalactiae at any time during pregnancy

          -  Multifetal pregnancy

          -  Breech presentation

          -  Stillbirth

          -  Any contraindication for vaginal delivery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Àngels Vives Argilagós, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consorci Sanitari de Terrassa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Àngels Vives Argilagós, MD</last_name>
    <phone>+34 937310007</phone>
    <phone_ext>7098</phone_ext>
    <email>MAVives@cst.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marino Romero Ramírez, MD</last_name>
    <phone>+34 937310007</phone>
    <phone_ext>2319</phone_ext>
    <email>marino.rora@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Consorci Sanitari de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08227</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angels Vives Argilagós, MI</last_name>
      <phone>937310007</phone>
      <phone_ext>7098</phone_ext>
      <email>MAVives@cst.cat</email>
    </contact>
    <contact_backup>
      <last_name>Marino Romero Ramirez, MI</last_name>
      <phone>937310007</phone>
      <phone_ext>3319</phone_ext>
      <email>marino.rora@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2016</study_first_submitted>
  <study_first_submitted_qc>May 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2016</study_first_posted>
  <last_update_submitted>May 11, 2016</last_update_submitted>
  <last_update_submitted_qc>May 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Consorci Sanitari de Terrassa</investigator_affiliation>
    <investigator_full_name>Dra Angels Vives Argilagós</investigator_full_name>
    <investigator_title>Obstetrician</investigator_title>
  </responsible_party>
  <keyword>cervical ripening</keyword>
  <keyword>misoprostol</keyword>
  <keyword>supracervical balloon</keyword>
  <keyword>Foley catheter</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

